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Abstract: Glycoprotein B (gB) plays an important role in alphaherpesvirus cellular entry 
and acts in concert with gD and the gH/gL complex. To evaluate whether functional 
differences exist between gB1 and gB4, the corresponding genes were exchanged between 
the two viruses. The gB4-containing-EHV-1 (EHV-1_gB4) recombinant virus was analyzed 
for growth in culture, cell tropism, and cell entry rivaling no significant differences when 
compared to parental virus. We also disrupted a potential integrin-binding motif, which did 
not affect the function of gB in culture. In contrast, a significant reduction of plaque sizes 
and growth kinetics of gB1-containing-EHV-4 (EHV-4_gB1) was evident when compared 
to parental EHV-4 and revertant viruses. The reduction in virus growth may be attributable 
to the loss of functional interaction between gB and the other envelope proteins involved in 
virus entry, including gD and gH/gL. Alternatively, gB4 might have an additional function, 
required for EHV-4 replication, which is not fulfilled by gB1. In conclusion, our results show 
that the exchange of gB between EHV-1 and EHV-4 is possible, but results in a significant 
attenuation of virus growth in the case of EHV-4_gB1. The generation of stable recombinant 
viruses is a valuable tool to address viral entry in a comparative fashion and investigate this 
aspect of virus replication further. 
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1. Introduction 
Glycoprotein B (gB) is a type 1 transmembrane protein and represents a highly conserved class III 
fusion protein present in members of the Herpesviridae family [1]. In members of the 
Alphaherpesvirinae, it is thought that gB mediates the virus entry process through membrane fusion after 
initial attachment of the virion via gC to cell surface glycosaminoglycans, binding of gD to its cognate 
receptor and activation of the heterodimeric gH-gL complex, which in turn primes gB for fusion [2–9]. 
In Herpes simplex virus type 1 (HSV-1), gB has been shown to bind several cellular receptors to facilitate 
viral entry; however, there is no data available on the role of equine herpesvirus type 1 (EHV-1) gB in 
receptor binding [1]. HSV-1 gB can bind to the paired immunoglobulin-like type 2 receptor (PILRα) to 
trigger viral fusion in the presence of gD [10]. In addition to PILRα, non-muscle myosin heavy chain 
IIA (NMMHCIIA; also known as myosin 9) [11] and myelin-associated glycoprotein (MAG) [12],  
a protein expressed in neuronal tissues, were also shown to interact with gB and facilitate HSV-1 entry 
although it has remained unclear whether specific gB-receptor interactions are critical for entry. 
Crystal structures of HSV-1 [13] and Epstein–Barr virus (EBV) [14] demonstrated that gB has 
structural similarity with other viral fusion proteins, such as the G protein of vesicular stomatitis virus 
(VSV) [15] and gp64 of baculovirus [16], and likely acts as the key herpesviral fusion protein that 
requires gH/gL as a fusion regulator [17–20]. However, it is not fully understood how gB and gH/gL 
interact during viral fusion. 
EHV-1 gB was first described in 1985 as antigenically and structurally similar to HSV-1 gB [21]. 
Later, it was shown that, like gB of other alphaherpesviruses, EHV-1 gB is essential for viral growth and 
direct cell-to-cell spread. This was deduced from the fact that only single infected cells, but no viral 
plaques, were observed when EHV-1∆gB was used to infect non-complementing cell lines. A strong 
indication for its role as a fusogen was also reported; when viral titers of a gB-deficient EHV-1 virus 
could partly be restored by adding polyethylene glycol to induce fusion [3]. However, there is no data 
available on the function of EHV-4 gB, the close relative of EHV-1. 
EHV-4 (145 kbp) and EHV-1 (150 kbp) both contain 76 unique and highly similar genes. Nucleic 
acid identity between EHV-4 and EHV-1 genes in general is above 80%, indicating that they are 
functionally closely related [22–24]. However, despite this high genetic similarity, the disease outcomes 
after infection differ substantially. EHV-4 only induces mild symptoms that are usually limited to upper 
respiratory tract infections associated with fever and general malaise [25,26]. While also causing 
respiratory disease, EHV-1 induces more severe clinical disease that includes abortion in pregnant  
mares [27–29] and the so-called EHV-1 myeloencephalopathy (EHM) [30,31]. On the cellular level, 
numerous differences in viral-cell interaction have been described. For instance, both viruses enter cells 
trough different pathways. More specifically, EHV-1 enters equine epithelial cells via direct fusion at 
the plasma membrane, while EHV-4 does so via an endocytic pathway [32]. 
The close genetic relatedness allowed us to exchange essential genes between EHV-1 and EHV-4 and 
to evaluate the effects both in vitro and in vivo in a way not possible for other members of the subfamily 
since EHV-1 and EHV-4 naturally infect the same host. We have been interested in exchanging 
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glycoproteins that are part of the cell entry complex between EHV-1 and EHV-4 to further elucidate the 
process of virus entry [32–35]. So far, gD was found to play an essential role in determining the cellular 
tropism of EHV-1 and EHV-4 in culture [33]. gH on the other hand was shown to be responsible for 
differences in the entry route taken by EHV-1 and EHV-4 [32]. We were interested in exchanging gB to 
uncover possible functional differences between the two viruses, thereby further elucidating the role of 
gB in tropism and pathogenicity. gB is highly similar between EHV-1 and EHV-4 and the proteins share 
an amino acid identity of 81.1% (Figure 1). 
 
Figure 1. Amino acid sequence alignment of Equine Herpesvirus Type 1 and Type 4  
(EHV-1 and EHV-4) glycoprotein B (gB). The putative integrin-binding motif  
tyrosine-glycine-leucine (YGL) present in the extracellular domains of both gB1 and gB4 
(red frame). gB1 and gB4 exhibit 81.1% sequence identity. Sequences were aligned using 
Vector NTI software (version 9, Invitrogen, Carlsbad, CA, USA, 2004). 
gB also contains a putative integrin-binding motif, tyrosine-glycine-leucine (YGL), which is 
conserved in both EHV-1 and EHV-4, and can potentially interact with α4β7, α4β1, and α9β1 integrins [36]. 
YGL is also present in the VP4 spike protein of rotaviruses where it mediates cell entry [36]. In a recent 
study, a similar integrin binding motif, leucine-aspartic acid-isoleucine (LDI), present in EHV-1 gH and 
interacting with cellular α4β1 integrins, has been implicated in determining the entry pathway taken by 
EHV-1 in equine cells [32]. Since integrin-binding motifs were shown to have significant roles during 
viral infection, we addressed the role of YGL-motif during EHV-1 and EHV-4 entry. 
Here we show that exchanging gB between EHV-1 and EHV-4 resulted in the generation of stable 
recombinant viruses; however, a significant attenuation in the case of EHV-4_gB1 was evident. 
2. Materials and Methods 
2.1. Viruses 
EHV-1 strain Ab4 [isolated from a quadriplegic mare [37] was cloned as a bacterial artificial  
chromosome (BAC) by replacing the nonessential gp2 gene with a mini-F plasmid, containing a  
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chloramphenicol resistance gene and the enhanced green fluorescence protein (eGFP) gene,  
(Ab4∆gp2) [38–40]. The EHV-4 infectious BAC clone was generated by the insertion of a loxP-flanked 
BAC vector into the intergenic region between genes 58 and 59 [41]. Viruses were reconstituted after 
transfecting BAC DNA into human embryonic kidney (293T) cells, as described earlier [41–43]. 
Supernatant and cells were collected 48 h post-transfection, and high titer stocks of each virus were 
produced by passaging the transfection product on equine dermal (ED) cells. 
2.2. Plasmids 
Transfer plasmids encoding either EHV-1 or EHV-4 gB with a kanamycin resistance (KanR) gene 
were constructed. EHV-1 and EHV-4 gB genes were amplified by PCR using primers P1 and P2 or P3 
and P4 (Table 1). The PCR products were digested with the restriction enzymes XhoI and XbaI  
(New England Biolabs, NEB, Schwalbach, Germany) and inserted into the vector pBluescript II KS+ 
(pKS), resulting in recombinant plasmids pKSgB1 and pKSgB4. To construct pKSgB1-KanR and 
pKSgB4-KanR, the KanR gene was amplified by PCR from plasmid pEPkan-S using primers P5, P6, 
P7, and P8 (Table 1), digested with the appropriate restriction enzymes, and inserted into pKSgB1 and 
pKSgB4. Correct amplification and insertion were confirmed by Sanger sequencing (LGC Genomics, 
Berlin, Germany). 
Table 1. Oligonucleotide primers used in this study. 
Primer Product Sequence 
P1 gB1 aatctcgagatgtcctctggttgccgttc 
P2 gB1 aactctagattaaaccattttttcatttt 
P3 gB4 aatctcgagatgtccacttgttgccgtgc 
P4 gB4 acatctagattaaaccattttttcgcttt 
P5 KanR 1 accggatccaccgtcgtacgcatcgaaccaggatgacgacgataagtaggg 
P6 KanR 1 ggtggatccggtaggcggtgggcaggtgtcaaccaattaaccaattctgattag 
P7 KanR 4 actggatccacagttgtacgcattgaaccaggatgacgacgataagtaggg 
P8 KanR 4 tgtggatccagtaggcggcgggcaggtgtcaaccaattaaccaattctgattag 
P9 gB1 deletion agcgctgcgtgagcggcatttacataacctacgaggcgtcacatgtttaataaatattataggatgacgacgataagtaggg 
P10 gB1 deletion tcacactttgagtacgtgtcataatatttattaaacatgtgacgcctcgtaggttatgtacaaccaattaaccaattctgattag 
P11 gB4 deletion agcgctgcgctagcggcatttacataacatacgagacgtcaaatgttaaataaatattttaggatgacgacgataagtaggg 
P12 gB4 deletion tcaacccacaagtacgtgtcaaaatatttatttaacatttgacgtctcgtatgttatgtacaaccaattaaccaattctgattag 
P13 gB4 KanR agcggcgcacagcgctgcgtgagcggcatttacataacctacgaggcgtcatgtccacttgttgccgtgc 
P14 gB4 KanR aaatatgaggtcacactttgagtacgtgtcataatatttattaaacatgtttaaaccattttttcgcttt 
P15 gB1 KanR aacggcgcacagcgctgcgctagcggcatttacataacatacgagacgtcatgtcctctggttgccgttc 
P16 gB1 KanR caaatatgagtcaacccacaagtacgtgtcaaaatatttatttaacatttttaaaccattttttcatttt 
P17 gBY336A ctgtccaccggtgatattgtgtacgcgtctccgtttGCcggcctgagggctgccgctcgcaggatgacgacgataagtaggg 
P18 gBY336A gtagctattgtgctctatgcgagcggcagccctcaggccgGCaaacggagacgcgtacaccaaccaattaaccaattctgattag 
P19 Sequencing ctcggttttccactgtggag 
P20 Sequencing ggtgaatgaggatgaaacct 
P21 Sequencing cgaccacgccaagccccccaac 
P22 Sequencing cggcctcccccactttacccag 
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Table 1. Cont. 
Primer Product Sequence 
P23 Sequencing atcgaaccacctagaacttg 
P24 Sequencing gtcagctggaactggac 
P25 Sequencing gggcgggagtagcacgtgtt 
P26 Sequencing agccccccaaatgggttgt 
P27 Sequencing ccacggtcatgtcccaagtt 
P28 Sequencing ttctcttcggttttccactg 
P29 Sequencing ttggcaaaaatactaggctt 
Restriction enzyme sites are given in lower case bold letters; sequences in italics indicate additional bases 
which are not present in the EHV-1 or -4 sequence; Underlined sequences indicate the template binding region 
of the primers for PCR amplification with pEPkan-S; Upper case bold letters indicate the nucleotides that  
were mutated. 
2.3. Cells 
293T, Rabbit kidney (RK13), Henrietta Lacks (HeLa), African green monkey kidney (Vero), Crandell 
feline kidney (CrFK) and Madin-Darby canine kidney (MDCK) cells were propagated in Dulbecco’s 
modified Eagle’s medium (DMEM; Biochrom AG, Berlin, Germany) supplemented with 10% fetal 
bovine serum (FBS; Biochrom AG), and 1% penicillin-streptomycin. ED, Chinese hamster ovary 
(CHO)-K1, and CHO cells expressing HevA, HevB, and HevC (CHO-A, CHO-B and CHO-C cells, 
respectively; a kind gift from Dr. Patricia Spear, Northwestern University, Chicago, IL, USA) were 
grown in Iscove’s modified Dulbecco’s medium (IMDM; Invitrogen, Paisley, UK) supplemented with 
20% FBS, 1% nonessential amino acids (Biochrom AG) and 1% 100 mM sodium pyruvate (Biochrom AG). 
For generation of Vero cells, which transiently express EHV-4 gB (Vero/gB4), cells were transfected 
with the vector pcDNA3 (Invitrogen, Paisley, UK) containing gB4  using Lipofectamine 2000 (Invitrogen, 
Paisley, UK). 
Peripheral blood mononuclear cells (PBMC) were isolated from heparinized blood collected by 
density gradient centrifugation over Histopaque 1077 (Sigma, St. Louis, MO, USA), following the 
manufacturer’s instructions. After two washing steps, cells were suspended in RPMI 1640 supplemented 
with 10% FBS, 0.3 mg/mL glutamine, non-essential amino acids, and 1% penicillin-streptomycin. 
2.4. BAC Mutagenesis 
The generated BACs were maintained in Escherichia coli (E. coli) GS1783 (a kind gift from  
Greg Smith, Northwestern University, Chicago, IL, USA), which harbor the recombination system of 
phage λ under the control of a temperature-sensitive repressor [44]. Deletion of the gB gene (UL27) in 
EHV-1 and EHV-4 was done by a two-step recombination method (Figure 2) as described before [45]. 
Briefly, primers P9, P10, P11, and P12 (Table 1) were used to generate homology arms (50 nucleotides) 
by PCR enabling the substitution of gB by KanR. PCR products were digested with DpnI in order to 
remove residual template DNA. The fragments were then transformed into GS1783 cells containing the 
BACs by electroporation. Kanamycin-resistant colonies were purified and screened by PCR and 
restriction fragment length polymorphism (RFLP) to detect correctly recombinant clones. Positive 
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clones were subjected to a second round of Red recombination, excising the KanR gene, to obtain the 
intermediate constructs pEHV-1∆gB and pEHV-4∆gB. 
 
Figure 2. Schematic diagram of the procedures used to construct mutant genomes  
(EHV-1_gB4 as model). The two unique regions (UL and US) of the EHV-1 genome as well 
as the terminal and internal repeat sequences (TRS and IRS) are shown, as is the inserted 
mini-F cassette. PCR products of the kanamycin resistance gene (KanR) were transformed 
into GS1783 containing the EHV-1 bacterial artificial chromosomes (BACs) by 
electroporation and the first step of the Red recombination method ensued. In the second 
step of Red recombination, the KanR gene was excised, thereby obtaining the pEHV-1∆gB 
deletion construct. The PCR-amplified gB4Kan was then electroporated into GS1783 
harboring pEHV-1∆gB, and, again, two-step Red recombination was performed to obtain 
the final construct pEHV-1_gB4. 
The transfer gB1Kan and gB4Kan sequences were amplified by PCR using pKSgB1-KanR and 
pKSgB4-KanR as templates and primers P13, P14, P15, and P16 (Table 1). PCR products were then 
electroporated into GS1783 harboring pEHV-1∆gB or pEHV-4∆gB. After selection on LB agar plates 
containing 34 μg/mL chloramphenicol and 50 μg/mL kanamycin, resistant colonies were purified  
and screened by PCR and RFLP to detect E. coli harboring recombinant pEHV-1_gB4Kan and  
pEHV-4_gB1Kan. Positive clones were subjected to a second round of Red recombination to obtain  
the final constructs pEHV-1_gB4 and pEHV-4_gB1. 
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A point mutation targeting the YGL motif present in EHV-1 gB was generated by introducing alanine 
into the tyrosine position (EHV-1_gBY336A). Mutants were generated through two-step red 
recombination using primers P17 and P18 (Table 1) as described above. 
The respective genotypes of all the mutants and revertants were confirmed by PCR, RFLP, and Sanger 
sequencing (primers P19-P29; Table 1; data not shown). 
2.5. Western Blot Analysis 
For Western blot analyses, pellets of infected ED cells were suspended in radioimmunoprecipitation 
assay (RIPA) buffer (50 mM Tris (pH 7.4), 1% Triton X-100, 0.25% Na-deoxycholate, 150 mM sodium 
chloride, 1 mM EDTA) with the complete EDTA-free protease inhibitor cocktail (Roche, Basel, 
Switzerland). Sample buffer (1 M Tris-HCl (pH 6.8), 0.8% sodium dodecyl sulfate (SDS), 0.4% glycerol, 
0.15% β-mercaptoethanol, 0.004% bromophenol blue) was added to lysates, the mixture was heated at 
95 °C for 5 min, and proteins were separated by 10% SDS-polyacrylamide gel electrophoresis (PAGE) 
as described before [46]. Expression of gB was detected with anti-EHV-1 gB MAb 3F6, which is also 
cross-reactive with EHV-4 gB (1:1000) [47]. Rabbit anti-β-actin antibody (1:2000) (Cell signaling 
Technologies, Danvers, MA, USA) was included as a loading control. Goat anti-mouse or goat  
anti-rabbit (1:10,000) IgG peroxidase conjugates (Southern Biotech, Birmingham, AL, USA) were used 
as secondary antibodies. Reactive bands were visualized by enhanced chemiluminescence (ECL Plus; 
Amersham, GE Healthcare, Piscataway, NJ). 
2.6. Virus Growth Assays 
To determine differences in viral replication in culture, single step growth kinetics for EHV-1 and 
multi-step growth kinetics for EHV-4 were conducted as described before [34]. Briefly, confluent ED 
cells were infected with a multiplicity of infection (MOI) of 1 in case of EHV-1 parental virus,  
EHV-1_gB4 and EHV-1 revertant. An MOI of 0.1 was used for EHV-1_ gBY336A in comparisons with 
parental EHV-1. In case of parental EHV-4, EHV-4_gB1, and revertant EHV-4, an MOI of 0.01 was 
used. After 1 h, cells were washed and treated with citrate buffer (pH = 3). Infected cells and supernatant 
were collected separately for EHV-1 and combined for EHV-4 at the indicated times post infection (p.i.), 
and stored at −80 °C. Viral titers were determined on ED cells. 
Plaque size measurements were conducted by infecting ED cells for 1 h at 37 °C with an MOI of 
0.01, followed by removal of the virus suspension and overlay with DMEM containing 0.5%  
methylcellulose (Sigma). After 72 h.p.i, the diameters of 100 fluorescent plaques for each virus were 
measured using ImageJ software vl.32j (National Institutes of Health, Bethesda, MD, USA, 2004) 
(http://rsb.info.nih.gov/ij/). The obtained values were normalized and compared to the values of parental 
viruses, which were set to 100%. Three independent experiments were used to calculate average plaque 
sizes and standard deviations. 
2.7. Virus Infection Assay 
For evaluating efficiency of replication and cell tropism, confluent monolayers of different cell types 
were infected with an MOI of 0.1 of the respective viruses. Cells were then washed and overlaid with 
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the appropriate medium. After 48 h p.i, cells were inspected with immunofluorescence microscope 
(Zeiss Axiovert, Jena, Germany) and pictures were taken with an Axiocam CCD camera (Zeiss,  
Jena, Germany). 
2.8. Flow Cytometry 
One million PBMC were incubated with EHV-1 and the engineered recombinant viruses at an MOI 
of 1 for 48 h at 37 °C. After incubation, the percentage of infected cells was determined by measuring 
eGFP expression with a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA). 
2.9. Pharmacological Inhibitors 
Cells were pretreated with different drugs for 60 min as described before [32], and infected with 
parental and recombinant viruses using an MOI of 0.05 for 24 h in the presence of the drugs. Cells were 
then trypsinized and washed twice with PBS. After centrifugation, cells were resuspended in PBS, and 
10,000 cells were analyzed for eGFP expression with a FACSCalibur flow cytometer. The drug 
concentrations used were 100 μg/mL genistein (Sigma) dissolved in DMSO, 10 μg/mL chlorpromazine 
(Sigma) in PBS, and 80 μM dynasore (Sigma) in DMSO. 
2.10. Statistical Analysis 
Statistical analyses (described in context) were performed using GraphPad PRISM (Version 5, 
GraphPad Software Inc., La Jolla, CA, USA, 2007). Normally distributed datasets, determined with the 
Shapiro–Wilks test, were analyzed with one-way ANOVA. Datasets that were not normally distributed 
were analyzed with Kruskal–Wallis one-way analysis of variance for two or more samples that are 
independent or the Friedman test for repeated measures. 
3. Results 
3.1. gB Expression by the Recombinant Viruses 
To determine whether gB was properly expressed by the recombinant viruses, ED cells were infected 
with parental, recombinant and revertant viruses. Cell lysates were then collected and subjected to 
Western blot analysis. For parental EHV-1, EHV-4 and related recombinant viruses, proteins with 
molecular weights of approximately 138 and 76 kD were detected that were not present in mock-infected 
cells (Figure 3). This is in accordance with previous reports where a partially glycosylated precursor of 
approximately 138 kD and a fully glycosylated subunit of gB of 75–77 kD were reported to be 
specifically recognized by MAb 3F6 [48]. These experiments confirmed that all generated recombinant 
and revertant viruses expressed gB as expected. 
  




Figure 3. Expression of gB in virus-infected cells. Cell lysates were prepared from infected 
equine dermal (ED) cells and proteins were separated under reducing conditions by  
sodium dodecyl sulfate (SDS)-10%-polyacrylamide gel electrophoresis (PAGE). The blots 
were incubated with anti-gB monoclonal antibody (MAb)-3F6 and bound antibody detected 
with anti-mouse IgG peroxidase conjugate. EHV-1, EHV-4 and related recombinant virus 
proteins with an apparent molecular weight of approximately 130 and 76 kD were detected 
that are not present in mock-infected cells. Rabbit anti-β-actin antibody was used as a loading 
control (molecular weight of approximately 42 kDa). 
3.2. EHV-4 gB Is Essential for Viral Replication 
pEHV-4∆gB DNA was transfected into Vero cells and the cells were monitored for 48 h. Only single 
infected cells (eGFP-positive/fluorescent cells) could be detected of which the number did not increase 
over time (Figure 4a). In contrast, Vero cells transfected with parental EHV-4 DNA showed syncytium 
formation after 48 h (Figure 4c). When Vero cells, which were transfected with gB4 as described 
previously for gH [35], were transfected with EHV-4∆gB (Figure 4b), syncytium formation with a 
morphology similar to that induced by parental EHV-4 (Figure 4d) could be seen. 
 
Figure 4. Transfection of African green monkey kidney (Vero) cells with EHV-4ΔgB.  
EHV-4ΔgB DNA was transfected in Vero cells (a) and Vero/gB4 cells (b). Also, parental 
EHV-4 DNA was transfected in both Vero (c) and Vero/gB4 cells (d). After 48 h of 
incubation, cells were inspected with an epifluorescent microscope (Zeiss Axiovert, Jena, 
Germany) and images were taken with a CCD camera (Zeiss Axiocam, Jena, Germany). The 
bar represents 100 μm and the white frames contain magnified inserts of the selected areas. 
Plaque formation of the gB-negative EHV-4 mutant was only evident on Vero/gB4 but not 
parental Vero cells. 
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3.3. Virus Growth in Culture 
No significant differences were observed for any of the EHV-1 recombinants when compared to the 
parental virus (Figure 5a,c,d). We therefore concluded that the growth properties of recombinant  
EHV-1 in culture were not significantly affected by the exchange with EHV-4 gB. 
 
Figure 5. Growth characteristics of parental and recombinant EHV-1 and EHV-4 in cell 
culture. ED cells were infected with the respective viruses at a multiplicity of infection (MOI) 
of 0.01. Means ± SD of diameters of 100 plaques measured for each virus are shown. The 
plaque diameter of parental viruses was set to 100%. No significant differences (one-way 
ANOVA; p > 0.05) between parental EHV-1 and EHV-1_gB4 were obvious (a). A 
significant reduction (one-way ANOVA; p < 0.05) of plaque size for EHV-4_gB1 was 
evident when compared to parental and revertant virus. Means ± SD of diameters of 100 
plaques measured for each virus are shown. The plaque diameter of parental viruses was set 
to 100% (b). For single step growth kinetics of EHV-1 recombinant viruses, ED cells were 
infected at an MOI of 1 (c,d), followed by citrate treatment (pH = 3) to remove remaining 
extra-cellular virions. Infected cells (c) and supernatants (d) were separately collected and 
Viruses 2015, 7 532 
 
 
virus titers were determined at the indicated times post-infection (p.i). The data presented 
are means ± SD of three independent measurements. No significant differences were 
measured for the EHV-1 recombinant viruses when compared to the parental viruses 
(Friedman test-Dunn’s multiple comparison test; p > 0.05). (e) For multi-step growth kinetics 
of EHV-4_gB1, ED cells were infected at MOI of 0.01, followed by washing. Infected cells 
and supernatants were collected and virus titers were determined at the indicated times p.i. 
The data presented are means ± SD of three independent measurements. A significant 
decrease was measured for EHV-4_gB1 at several time points (*) when compared to the 
parental and revertant viruses (Friedman test–Dunn’s multiple comparison test; p < 0.05). 
In the case of EHV-4_gB1, however, significantly reduced plaque sizes were seen compared to  
parental and revertant viruses (Figure 5b). Similarly, EHV-4_gB1 also showed a significantly reduced 
growth rate at several time points as evidenced by the growth kinetics (Figure 5e). 
3.4. gB Has No Role in Determining the Host Range of EHV-1 and EHV-4 in Culture 
EHV-1 can replicate and spread in many cell lines from equine and other origin [49]. In contrast, 
EHV-4 appears to be restricted mainly to equine cells and replicates poorly in only few cell lines, such 
as Vero cells [43]. In order to investigate whether gB plays a role in determining host range, as already 
shown for gD [33], several cell lines that are only permissible for either EHV-1 or EHV-4 were infected. 
Contrary to the exchange of gD between the two viruses, no changes in permissiveness were seen after 
exchanging gB between EHV-1 and EHV-4 (Figure 6; Table 2). 
 
Figure 6. Cont. 





Figure 6. The role of gB in EHV-1 cellular tropism. Chinese hamster ovary (CHO)-K1, 
CHO-A, CHO-B, CHO-C, Crandell feline kidney (CrFK), Madin-Darby canine kidney 
(MDCK), Rabbit kidney (RK13) and Vero cells were infected at an MOI of 0.1 with the 
parental EHV-1 and EHV-1_gB4, all of which express eGFP. At 24 h p.i., cells were 
inspected with a fluorescent microscope (Zeiss Axiovert, Jena, Germany) and images were 
taken with a CCD camera (Zeiss Axiocam, Jena, Germany). The bar represents 100 μm and 
the white frames contain magnified inserts of the selected areas. CHO-K1, CHO-A, CHO-B 
and CHO-C, and RK13 cells were highly resistant and MDCK virtually resistant to parental 
and recombinant EHV-4 infection. In addition, CrFK were highly resistant and Vero cells 
virtually resistant to parental and recombinant EHV-1 infection. 
Table 2. The role of gB in EHV-1 cellular tropism. 
Cell line EHV-1 EHV-1 gB4 EHV-4 EHV-4 gB1 
CHO-K1 + + − − 
CHO-A + + − − 
CHO-B + + − − 
CHO-C + + − − 
CrFK − − + + 
MDCK + + + + 
RK13 + + − − 
Vero + + + + 
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3.5. The Integrin-Binding Motif YGL Is Not Involved in EHV-1 Entry 
The integrin-binding motif YGL was predicted with the I-TASSER server and is present in the  
extracellular domain of gB (http://zhang.bioinformatics.ku.edu/I-TASSER/). The motif is conserved in 
both EHV-1 and EHV-4. The YGL motif was mutated into AGL in EHV-1 (EHV-1_gBY336A) to evaluate 
its importance for cell entry and determining the cell entry pathway. 
In previous studies, function-blocking MAbs α4β1 and α4β7 were used to investigate the role of  
integrins during entry into PBMC, ED and fetal horse kidney (FHK) cells. It was shown that blocking 
these potential receptors for EHV-1 and EHV-4 had no effect on their growth in culture or their ability 
to infect PBMC [35]. However, this does not exclude the possibility that the YGL motif could have an 
effect on viral growth and infection rates, since other unknown binding partners could be involved. 
However, no changes could be seen for either viral growth in culture (Figure 7a,c,d) or infection rates in 
PBMC (Figure 7b) between parental EHV-1 and EHV-1_gBY336A. 
 
Figure 7. Characterization of EHV-1_gBY336A. (a) ED cells were infected with the  
respective viruses at an MOI of 0.01. Means ± SD of diameters of 100 plaques measured for 
each virus are shown. The plaque diameter of parental viruses was set to 100%. No  
significant differences (one-way ANOVA; p > 0.05) between parental EHV-1 and  
EHV-1_gBY336A were evident; (b) One million peripheral blood mononuclear cells 
(PBMC) were incubated with parental and recombinant EHV-1 viruses at an MOI of 1 for 
24 h at 37 °C. After incubation, the percentage of infected cells was determined by flow 
cytometry. The rate of infection of parental virus was set to 100%. All data represent the 
means ± SD of three independent experiments (Kruskal–Wallis one-way analysis of 
variance; p > 0.05). For single-step growth kinetics of EHV-1 recombinant viruses, ED cells 
were infected at an MOI of 0.1 (c,d), followed by citrate treatment (pH = 3) to remove 
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remaining extracellular virions. Infected cells (c) and supernatants (d) were separately 
collected and virus titers were determined at the indicated times p.i. The data presented are 
means ± SD of three independent measurements. No significant differences were detectable 
for the EHV-1 recombinant viruses when compared to the parental viruses (Friedman  
test–Dunn’s multiple comparison test; p > 0.05). 
3.6. gB and YGL Do Not Play a Role in Determining the Cell Entry Pathway 
To investigate whether gB or the YGL motif have an effect on the viral entry pathways used by  
EHV-1, we conducted inhibitor studies using drugs that target various cellular functions associated with 
viral cell entry as described previously for gH [32]. 
Caveolae are plasma membrane invaginations that play an important role in cellular uptake of  
EHV-4 or EHV-1 after replacing authentic gH1 with EHV-4 gH [32]. Caveolae-mediated uptake  
depends on dynamin II [50], which can be inhibited by dynasore [51], and tyrosine kinases, which can 
be inhibited by genistein [52]. Chlorpromazine affects Clathrin-mediated endocytosis through the  
inhibition of Clathrin adaptor protein 2 assembly [53]. Since this drug does not affect the uptake of  
EHV-1 and EHV-4 [32], it was used as a negative control. 
Contrary to the differences in cell entry pathway seen when exchanging gH, no significant differences 
could be seen between parental EHV-1 and EHV-1_gB4 or EHV-1_gBY336A after using different 
inhibitors. In the case of EHV-4_gB1 as well as parental EHV-4, the number of infected cells was 
significantly reduced when treated with either genistein or dynasore. These data clearly indicated that 
gB has no role in routing the entry pathway of EHV-1 (Figure 8), but is rather required for entry steps 
after receptor binding. 
 
Figure 8. Cont. 




Figure 8. Inhibition of cell entry. Equine dermal (ED) cells were treated with the inhibitors 
genistein (Gen; a), dynasore (Dyn; b) and chlorpromazine (Chlo; c), as indicated, before 
infection with parental or recombinant viruses at an MOI of 0.05. At 24 h p.i., cells were 
washed and the percentage of infected cells was determined by flow cytometry. The 
percentage of infection of the parental virus was set to 100%. The percentage of infection 
(eGFP+) in the absence of inhibitors was set to 100%. All data represent the means ± SD of 
three independent experiments. Significant decreases (*) were only seen for EHV-4_wt in 
the presence of dynasore and genestein (Kruskal–Wallis one-way analysis of variance;  
p < 0.05). However, no significant differences in infection rate were seen between parental 
and recombinant viruses in the different settings (Kruskal–Wallis one-way analysis of 
variance; p > 0.05). 
4. Discussion 
For several alphaherpesviruses, including EHV-1, it has been shown that gB is essential for  
infection [7,54–58]. More specifically, gB plays an important role in the cell-to-cell spread of  
alphaherpesviruses [2–6]. In the present study, we have addressed the importance of gB for EHV-4  
replication. We have shown that the number of infected cells after transfection with pEHV-4∆gB did not 
increase over time. This suggests that EHV-4 is not able to either be released from infected cells or enter 
uninfected cells without the help of gB. The gB-deleted virus was only able to induce syncytium  
formation when grown in pcDNAgB4-transfected Vero cells, in other words when the glycoprotein was 
provided in trans. It has been shown that gB is involved in virus maturation and egress from the infected 
cells for different herpesviruses including HSV-1 and Kaposi’s sarcoma-associated herpesvirus [59,60]. 
EHV-4 gB may also play a role in viral egress, including first or secondary envelopment or virion release 
into the extracellular space. However, we view an involvement of EHV-4 gB in egress as unlikely as 
those of other varicelloviruses are not required in the process either. Rather, we presume an essential 
role in virus entry and cell-to-cell spread but the exact role and the mechanism are not known at present 
and need to be further investigated. Taken together, the essentiality of gB functions during different virus 
replication steps is not unique to EHV-4 as all of the gB homologues across all subfamilies of the 
Herpesviridae studied until now have been shown to play similar roles. 
The replacement of gB1 by gB4 in EHV-1 did not lead to significant changes in viral growth in 
culture. However, the EHV-4_gB1 recombinant exhibited a markedly reduced growth defect as 
evidenced by impaired viral cell-to-cell spread and reduced growth kinetics. This was particularly 
surprising since no apparent growth defect was seen in culture during previously conducted experiments 
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where gB were exchanged between alphaherpesviruses of different natural hosts [61]. The growth defect 
of EHV-4_gB1 could be caused by a structural incompatibility of gB1 that EHV-4 was unable to 
compensate for. Alternatively, gB4 might have an additional role required for EHV-4 replication but not 
fulfilled by gB1. In a previous study, where gB of HSV-1 was replaced with gB of Saimiriine 
Herpesvirus 1 (SaHV-1), it was shown that HSV-1 gB possessed and additional function lacking for 
SaHV-1 gB. Loss of functional interaction with PIRLα was reported for SaHV-1 despite sequence 
alignment suggesting that the interaction site is conserved [62]. 
Therefore, it would be interesting to further elucidate the structural differences between gB1 and gB4 
and identify putative viral interaction partners of gB. After binding of gD to cellular receptors it activates 
gH-gL complex, which in turn primes gB for fusion. Perhaps, the authentic EHV-4 gH-gL complex 
could not prime gB1 as efficiently as the native gB4 for fusion. It will, therefore, be interesting to 
examine whether a triple mutant, i.e., EHV-4 harboring gH1-gL1-gB1 and vice versa, would lead to any 
changes of the virus’ ability to effectively replicate. 
Recently it was shown that EHV-1 gD, besides its primary interaction partner MHC class I, can bind 
to a wide array of receptors and that it is responsible for determining the host range of the virus. The 
case is less clear for EHV-4 gD, which also uses MHC class I as an entry receptor and likely another 
molecule to enter, e.g. Vero cells [33]. In the current study, we showed that exchanging gB has no effect 
on the entry of the recombinant viruses into the selected cell lines, suggesting that gB is not important 
in determining cellular host range. It seems likely that, in contrast to HSV-1 [10–12], gB of EHV-1 or 
EHV-4 does not need to bind to different cellular receptors to facilitate fusion, that gB binding is not 
important for cellular tropism, or that gB and receptor interaction are not absolutely required for entry. 
However, this conclusion does not exclude the role of gB, together with gC, to bind cell surface heparan 
sulfate and help the attachment of virions to cells during the initial events of infection [34]. 
Disrupting the integrin-binding motif YGL in gB1 did not have any effect on virus growth in culture. 
Furthermore, YGL apparently does not play a decisive role in determining the cell entry pathway of 
EHV-1 or EHV-4. These results are in accordance with previous work where binding between the 
integrin-binding motif YGL and selected known ligands α4β1 or α4β7 was mitigated using blocking 
antibodies. These experiments revealed that YGL does not need to interact with its known binding 
partners for infection [35]. From these results, we concluded that gB-integrin interaction does not play 
an important role in cell entry or determining the cell entry pathway; however, it may have a role in 
signaling transduction that might be needed during other steps of virus replication. Furthermore, these 
data do not necessarily mean that no interaction occurs between EHV-1 and the respective integrins. The 
integrins may serve as a receptor and/or co-receptor for viral entry and their blockade may not have a 
measurable effect on virus infection, especially, if alternative receptors exist. 
Due to its importance in cell-to-cell spread [6], gB would be an interesting target for future research 
on the spread of EHV-1 between infected PBMC and endothelial cells (EC). This process enables  
infection of EC even in the presences of neutralizing antibodies, causing vascular lesions and secondary 
hypoxic degeneration of affected tissues [24,63]. 
In summary, the replacement of gB1 by gB4 in EHV-1 did not lead to any significant changes in viral 
growth in culture compared to EHV-1. However, EHV-4 seems to be unable to fully compensate the 
structural changes introduced by the replacement of gB4 with gB1 with respect to replication in culture. 
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Nonetheless, the generation of a stable EHV-1_gB4 recombinant virus gives us the tools to address viral 
entry and spread of EHV-1 and EHV-4 in other cell types in the future. 
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